Scarica l'app Stockscreener
170.51
1.36%
-2.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABBV Giù?
Forum
Previsione
Storia dei dividendi
Abbvie Inc Borsa (ABBV) Ultime notizie
Jim Cramer Is Bullish on AbbVie Inc. (ABBV) Ahead of Earnings - Yahoo Finance
AbbVie price target lowered to $200 from $223 at BofA - TipRanks
BofA Adjusts AbbVie (ABBV) Price Target Ahead of Q1 Results | ABBV Stock News - GuruFocus
Immunology Drugs Market Top Companies Study- Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer. - openPR.com
Is AbbVie Stock a Buy? - MSN
Lobbying Update: $50,000 of ABBVIE INC. lobbying was just disclosed - Nasdaq
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView
Is AbbVie Inc. (ABBV) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Shares Sold by Canada Pension Plan Investment Board - MarketBeat
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - marketscreener.com
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
AbbVie (ABBV): A Top Dividend Monarch with Strong Growth Prospects - GuruFocus
Applications now open for Abbvie’s cystic fibrosis scholarship program - Cystic Fibrosis News Today
AbbVie (ABBV) Gets a Buy from Guggenheim - The Globe and Mail
Fund Update: Bank Pictet & Cie (Europe) AG added 78,930 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
10 Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now - Insider Monkey
Interleukin Inhibitors Market Is Booming Worldwide | AbbVie - openPR.com
Drug company files suit against South Dakota over new 340B law - South Dakota Public Broadcasting
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks - Yahoo Finance
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment - Yahoo Finance
Top Research Reports for AbbVie, TJX & Charles Schwab - MSN
AbbVie Asks Court to Extend Venclexta Cancer-Drug Patent’s Life - Bloomberg Law News
AbbVie Options Trading: A Deep Dive into Market Sentiment - Nasdaq
AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Drugmaker sues SD over law preserving broad access to discounts for hospitals, pharmacies - Argus Leader
The Zacks Analyst Blog Merck and AbbVie - Yahoo Finance
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie and Sandoz agree to drop court spat over Rinvoq patents - Endpoints News
ABBV vs. MRK: Which Drug Giant is a Better Buy Now? - Yahoo Finance
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
The Zacks Analyst Blog Merck And AbbVie - Barchart.com
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Earnings Preview: What to Expect From AbbVie's Report - Nasdaq
Earnings Preview: What To Expect From AbbVie's Report - Barchart.com
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Yahoo Finance
10 High Growth Forever Dividend Stocks To Invest In - Insider Monkey
Is AbbVie Inc. (ABBV) the Best Stock for 15 Years? - Insider Monkey
Skin Boosters Market to Witness Stunning Growth with AbbVie, Medytox, ExoCoBio - openPR.com
AbbVie (ABBV) Faces Volatility Despite Positive Earnings in Q1 2 - GuruFocus
AbbVie, Sandoz Settle Patent Fight Over Rinvoq Generics - Law360
Multiple Myeloma Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
AbbVie Unusual Options Activity - Benzinga
AbbVie (NYSE:ABBV) Shares Down 5.6%Should You Sell? - MarketBeat
AbbVie Aesthetics Line Faces Potential Risk in Current Macro Environment, UBS Says - MarketScreener
AbbVie Brings New Suits Against State Pharmacy Contract Laws - Bloomberg Law News
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More - TradingView
1.13%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):